RECCE PHARMACEUTICALS LTD — Director's Dealing 2019

Aug 13, 2019

Change of Director's Interest Notice

SYDNEY Australia 14 August 2019: Recce Pharmaceuticals Ltd ('Recce') advises that Michele Dilizia, Director, has sold 45,000 Recce fully paid ordinary shares. Ms Dilizia will use the proceeds of the share sale, and the sales announced on 8 August 2019, to fund personal tax liabilities. Ms Dilizia does not expect to complete any further selling of Recce shares in the near term.

Ms Dilizia's holdings are set out below in the attached Appendix 3Y.

About Recce Pharmaceuticals

Recce Pharmaceuticals Ltd (ASX: RCE) is pioneering the development of a New Class of Synthetic Antibiotics with Broad Spectrum activity, addressing the urgent global health problem of antibiotic resistant superbugs. Its patented lead candidate RECCE® 327 has been designed for the treatment of blood infections and sepsis derived from E. coli and S. aureus bacteria – including their superbug forms. The FDA awarded RECCE® 327 Qualified Infectious Disease Product (QIDP) designation under the Generating Antibiotic Initiatives Now (GAIN) Act - labelling RECCE® 327 for Fast Track designation, plus 10 years of market exclusivity post approval. Recce's expanding anti-infective pipeline seeks to exploit the unique capabilities of RECCE® technologies targeting synergistic, unmet medical needs.

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

	Name of entity Recce Pharmaceuticals Ltd (Company)
ACN	124 849 065

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Michele Keryn Dilizia
Date of last notice	8 August 2019

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct Interest
Nature of indirect interest(including registered holder)Note: Provide details of the circumstances giving rise to the relevantinterest.	N/A
Date of change	8 August 2019
No. of securities held prior to change	2,609,061 fully paid ordinary shares577,212 Class B Performance Shares(and any fully paid ordinary sharesissued on conversion)577,212 Class C Performance Shares(and any fully paid ordinary sharesissued on conversion)577,212 Class D Performance Shares(and any fully paid ordinary sharesissued on conversion)
Class	Fully paid ordinary shares
Number acquired	Nil

+ See chapter 19 for defined terms.

Number disposed	45,000 fully paid ordinary shares
Value/ConsiderationNote: If consideration is non-cash, provide details and estimatedvaluation	$9,975.00
No. of securities held after change	2,564,061 fully paid ordinary shares
	577,212 Class B Performance Shares(and any fully paid ordinary sharesissued on conversion)
	577,212 Class C Performance Shares(and any fully paid ordinary sharesissued on conversion)
	577,212 Class D Performance Shares(and any fully paid ordinary sharesissued on conversion)
Nature of changeExample: on-market trade, off-market trade, exercise of options,issue of securities under dividend reinvestment plan, participation inbuy-back	On-market saleof 45,000fully paidordinary shares

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder(if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior tochangeNote: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/ConsiderationNote: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

+ See chapter 19 for defined terms.

Part 3 – +Closed period

Were the interests in the securities or contracts detailed abovetraded during a +closed period whereprior written clearance wasrequired?	No
If so, was prior written clearance provided to allow the trade toproceed during this period?	N/A
If prior written clearance was provided, on what date was thisprovided?	N/A

+ See chapter 19 for defined terms.